Alphatec Holdings is trading at $8.53, down 24.98%, after Q3 revenue missed consensus and the company lowered its 2026 outlook. - Q3 revenue was $221 million, below the $225 million consensus; management cited lower biologics attachment. - The 2026 revenue outlook is approximately $862 million; results were released after the October 29 market close. - Case volume grew 20% and free cash flow was $6 million; the release did not report trading volume or quantify the stock-market reaction.